Hereditary predisposition to cancer associated with the RAD51C gene is due to heterozygous pathogenic variants that alter DNA repair by homologous recombination. It is inherited in an autosomal dominant manner and mainly increases the risk of epithelial ovarian or fallopian tube cancer and breast cancer, with incomplete penetrance. Loss of RAD51C function favors genomic instability and tumor transformation.
Hereditary cancer (RAD51C gene)
The RAD51C gene encodes the RAD51C protein, one of the RAD51 recombinase paralogs. This protein is part of the BCDX2 and CX3 complexes, which act in different stages of homologous recombination, stabilize RAD51 filaments, and contribute to repairing double-strand DNA breaks and protecting replication forks.
When one copy of RAD51C loses its function, the ability to faithfully repair DNA decreases. The healthy copy may be inactivated in the tumor, leading to homologous recombination deficiency, although this does not occur in all cases. The cumulative average risk up to 80 years is estimated at around 11% for tubo-ovarian cancer and 21% for breast cancer, but it varies depending on family history, other genetic modifiers, and non-genetic factors. Pathogenic variants are rare, and their population prevalence is not well-defined; founder effects have been described in specific populations.
Symptoms
Carrier individuals do not present manifestations before developing a tumor. Primary ovarian, fallopian tube, or peritoneal cancer usually appears in adulthood, with an increased risk especially after age 50, and can cause abdominal distension or pain, early satiety, urinary changes, or weight loss. Breast cancer also typically appears in adulthood and there is a higher proportion of estrogen receptor-negative and triple-negative tumors. The age of onset and evolution are variable, and many carrier individuals never develop cancer. No clinically actionable associations with other tumors have been established.
Disease management
There is no treatment that eliminates genetic predisposition. Management is based on genetic counseling, individual risk estimation, and prevention or early detection. CA125 and transvaginal ultrasound do not reliably detect ovarian cancer in early stages; therefore, it is recommended to consider a risk-reducing bilateral salpingo-oophorectomy between 45 and 50 years of age, after completing childbearing desires, or earlier if there are earlier family cases. Breast surveillance should be adapted to the calculated risk and usually begins around age 40 with mammography, incorporating magnetic resonance imaging in high-risk women. Preventive mastectomy is not routinely indicated. Tumors are treated according to their location and characteristics; homologous recombination deficiency may influence the use of platinums or PARP inhibitors, but a germline variant alone does not guarantee therapeutic sensitivity.
Genes analyzed
Bibliography
eviQ Cancer Genetics Reference Committee. RAD51C or RAD51D – risk management (female). Cancer Institute NSW. 2026.
Yang X, Song H, Leslie G, et al. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. J Natl Cancer Inst. 2020;112(12):1242-1250.
Hu C, Hart SN, Gnanaolivu R, et al. Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C. Cancer Res. 2023;83(15):2557-2571.
Dawson LM, Smith KN, Werdyani S, et al. A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect. Mol Genet Genomic Med. 2020;8(2):e1070.
